Stock JBCHEPHARM J. B. CHEMICALS & PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings J. B. Chemicals & Pharmaceuticals Limited NSE India S.E.

Equities

JBCHEPHARM

INE572A01036

Delayed NSE India S.E.
Other stock markets
 11:01:57 31/05/2024 BST 		5-day change 1st Jan Change
1,772 INR +1.37% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited +6.25% +9.06%
05-22 Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,060 From INR2,000, Keeps at Buy MT
05-21 Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q4 2024 Earnings Call, May 21, 2024

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • With an expected P/E ratio at 45.07 and 38.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
J. B. CHEMICALS & PHARMACEUTICALS LIMITED Stock J. B. Chemicals & Pharmaceuticals Limited
+9.06% 3.24B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.82% 734B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.67% 591B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.31% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.23% 315B
B-
ABBVIE INC. Stock AbbVie Inc.
+0.86% 276B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.19% 238B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-6.30% 204B
A+
NOVARTIS AG Stock Novartis AG
+8.77% 206B
B-
AMGEN INC. Stock Amgen Inc.
+4.51% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JBCHEPHARM Stock
  4. JBCHEPHARM Stock
  5. Ratings J. B. Chemicals & Pharmaceuticals Limited